Dexmedetomidine for Sedation During Radiological Interventional Procedures

Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Inclusion Criteria:

• Age from 18-65 years old
• ASA physical status of I-II
• Expected procedure lasting at least 30 minutes

Exclusion Criteria:

• Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.
• An alpha2-agonist or antagonist within 14 days before the scheduled procedure.
• patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.
• Patients who are allergic to Dexmedetomidine or alpha 2-agonists.